Blood Pressure Interaction Between Sildenafil and Sublingual Glyceryl Trinitrate (GTN) in Men With Angina

NCT00479908

Last updated date
Study Location
University of Edinburgh
Edinburgh, Scotland, EH4 2XU, United Kingdom
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Angina Pectoris
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
30-80 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male

- Stable angina with one of:

- Classical history of exertional angina pectoris

- Previous diagnostic exercise test

- Angiographic evidence of CAD

- Aged 30 to 80 years

- Weight between 60 and 100 Kg

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Regular treatment with long-acting nitrates or nicorandil where these cannot be
withdrawn 72 hours prior to the study


- Myocardial infarction, unstable angina, stroke or transient cerebral ischaemia within
3 months


- Systolic BP > 170 mmHg or diastolic BP > 100 mmHg


- Systolic BP < 100 mmHg or diastolic BP < 60 mmHg


- Orthostatic hypotension (> 20 mmHg fall in systolic BP on standing)


- Diabetes treated with oral hypoglycaemic agents or insulin


- Any clinically significant disease other than stable angina, excepting other
cardiovascular disease risk factors, e.g. smoking, hypercholesterolaemia and
diet-controlled diabetes


- Taking any drug that interacts with sildenafil


- Evidence of drug abuse

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Angina PectorisBlood Pressure Interaction Between Sildenafil and Sublingual Glyceryl Trinitrate (GTN) in Men With Angina
NCT00479908
  1. Edinburgh, Scotland
Male
30 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Blood Pressure Interaction Between Sildenafil and Sublingual Glyceryl Trinitrate (GTN) in Men With Angina
Official Title  ICMJE Investigation of the Time Course of the Interaction of the Hypotensive Effects of Sildenafil Citrate and Sublingual Glyceryl Trinitrate (GTN) in Men With Stable Angina Pectoris
Brief Summary The purpose of the study is to determine for how long sildenafil potentiates the blood pressure reduction that occurs with glyceryl trinitrate in men with angina.
Detailed Description

By producing a mediator known as cGMP, nitric oxide (NO) potently dilates blood vessels. Nitrates, such as glyceryl trinitrate (GTN), are drugs that release NO (NO donors) and are widely used in the treatment and prevention of angina. Sildenafil is an effective treatment for male penile erectile dysfunction that inhibits the breakdown cGMP. When given alone it causes modest reductions in BP in healthy people and patients with cardiovascular disease. By their synergistic actions, co-administration of NO donors with sildenafil can result in large reductions in BP in patients with angina, a population at increased risk of developing erectile dysfunction. As a result, it is recommended that the two drugs not be co-administered within 24 hours of one another.

Previous studies have defined the effect of nitrates at 60 min after administration of sildenafil, the time of likely maximum interaction. However, emergency medicine physicians would value evidence of a balance of risks from which to make a personal clinical judgement about when they might consider giving GTN in a patient presenting with a severe episode of angina who has recently received sildenafil. Evidence on which to base such a judgement is currently not available. However, we have recently completed a study, showing that the interaction of GTN (0.4 mg spray) after sildenafil (100 mg) lasts less than 4 hours in healthy subjects. Whilst the findings would probably be similar for patients with angina, this question now needs to be investigated directly in order to ensure the generalisability of this work and address an important unresolved clinical issue.

Subjects will be asked to refrain from using short-acting nitrates for 24 hours and long acting nitrates for 72 hours before the start of the study. On the morning of each study visit subjects will take their normal medications, including anti-anginals, as soon as they wake up at home. They will also eat a light breakfast at home before coming to the research unit.

Subjects will attend 4 study visits, each separated by at least 5 days. At study visit 1 GTN will be administered 4 and 8 hours after oral sildenafil or matched placebo. At visit 2 GTN will be administered 4 and 8 hours after the alternative treatment (sildenafil or placebo). The order in which sildenafil and placebo are given will be randomised. At study visit 3 GTN will be administered 1 and 6 hours after sildenafil or placebo. Finally, at visit 4 GTN will be administered 1 and 6 hours after the alternative treatment (sildenafil or placebo). As with visits 1 and 2, the order in which sildenafil and placebo are given will be randomised.

Regular single measures of sitting and standing (after 2 min standing) BP and heart rate (HR) will be recorded at baseline and before and for 40 minutes after each GTN administration. Venous blood samples (20 mL) will be taken at baseline and immediately before and 40 min after each GTN administration for later determination of plasma concentrations of sildenafil and its active metabolite, UK-103,320.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Angina Pectoris
Intervention  ICMJE
  • Drug: Sildenafil citrate
  • Drug: Glyceryl trinitrate
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 29, 2007)
20
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE September 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male
  • Stable angina with one of:
  • Classical history of exertional angina pectoris
  • Previous diagnostic exercise test
  • Angiographic evidence of CAD
  • Aged 30 to 80 years
  • Weight between 60 and 100 Kg

Exclusion Criteria:

  • Regular treatment with long-acting nitrates or nicorandil where these cannot be withdrawn 72 hours prior to the study
  • Myocardial infarction, unstable angina, stroke or transient cerebral ischaemia within 3 months
  • Systolic BP > 170 mmHg or diastolic BP > 100 mmHg
  • Systolic BP < 100 mmHg or diastolic BP < 60 mmHg
  • Orthostatic hypotension (> 20 mmHg fall in systolic BP on standing)
  • Diabetes treated with oral hypoglycaemic agents or insulin
  • Any clinically significant disease other than stable angina, excepting other cardiovascular disease risk factors, e.g. smoking, hypercholesterolaemia and diet-controlled diabetes
  • Taking any drug that interacts with sildenafil
  • Evidence of drug abuse
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 30 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00479908
Other Study ID Numbers  ICMJE LREC/2003/8/35
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE University of Edinburgh
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:James J Oliver, MBChBUniversity of Edinburgh
PRS Account University of Edinburgh
Verification Date May 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP